Integra LifeSciences Holdings Co. (NASDAQ:IART) Stock Position Lessened by Arizona State Retirement System

Arizona State Retirement System decreased its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 2.4% in the 4th quarter, HoldingsChannel reports. The firm owned 20,481 shares of the life sciences company’s stock after selling 507 shares during the quarter. Arizona State Retirement System’s holdings in Integra LifeSciences were worth $892,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Itau Unibanco Holding S.A. grew its stake in shares of Integra LifeSciences by 469.5% in the second quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock worth $31,000 after purchasing an additional 615 shares in the last quarter. Gladius Capital Management LP bought a new position in shares of Integra LifeSciences in the third quarter worth $47,000. Covestor Ltd grew its stake in shares of Integra LifeSciences by 82.5% in the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 921 shares in the last quarter. Coppell Advisory Solutions LLC bought a new position in shares of Integra LifeSciences in the second quarter worth $84,000. Finally, Captrust Financial Advisors grew its stake in shares of Integra LifeSciences by 95.0% in the first quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock worth $129,000 after purchasing an additional 976 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

IART has been the subject of several research analyst reports. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. JMP Securities cut their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a report on Thursday, February 29th. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective for the company in a report on Wednesday, April 3rd. Finally, Truist Financial cut their price objective on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a report on Friday, March 1st. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $44.89.

Integra LifeSciences Trading Down 0.7 %

Shares of NASDAQ IART opened at $31.82 on Wednesday. Integra LifeSciences Holdings Co. has a 12 month low of $31.57 and a 12 month high of $59.30. The company has a market cap of $2.50 billion, a price-to-earnings ratio of 38.34, a P/E/G ratio of 0.99 and a beta of 1.12. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. The business has a fifty day simple moving average of $37.51 and a 200-day simple moving average of $39.24.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The company had revenue of $397.00 million for the quarter, compared to analysts’ expectations of $399.30 million. During the same period in the prior year, the company earned $0.94 earnings per share. The company’s revenue for the quarter was down .3% on a year-over-year basis. Sell-side analysts predict that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.